Recent advances in the diagnosis and treatment of deep vein thrombosis: a regional consensus.
Considerable progress has been made in the understanding of the risk factors for venous thromboembolism (VTE). The clinical applications of molecular techniques have allowed identification of important inherited, yet not uncommon, risk factors for VTE, such as mutations that cause Factor V Leiden and prothrombin G20210A. However, advances in our understanding have raised several questions regarding the need for, and duration of anticoagulation. At the end of the treatment period, low molecular weight heparins have become the drugs of choice and standard-of-care for VTE. In this review, cost effective diagnostic approaches for patients with suspected deep vein thrombosis, and recommended treatment options using evidence-based approaches, are described.
Qari
Mohamad
M
Department of Hematology, King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia. drqari@hotmail.com
Abdel-Razeq
Hikmat
H
Alzeer
Abdulaziz
A
Alizadeh
Hussein
H
Kristensen
Jorgen
J
al-Sayegh
Faisal
F
Qutub
Hatem
H
Marashi
Mahmoud
M
Husted
Steen
S
Mousa
Shaker
S
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006487:Hemostasis; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications; D011247:Pregnancy; D012307:Risk Factors; D015912:Thrombolytic Therapy; D020246:Venous Thrombosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology
D000925:Anticoagulants; D006493:Heparin